STEVENSON, Md., May 03, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Texas on behalf of purchasers of Adeptus Health Inc. (NYSE:ADPT) (“Adeptus” or the “Company”) securities during the period between April 29, 2016 and March 1, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until May 9, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Adeptus securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Adeptus had material weaknesses in its internal control over financial reporting in the areas of revenue recognition, accounts receivable, accounting for a contribution to an unconsolidated joint venture, and accounting for equity in (loss) earnings of unconsolidated joint ventures.
According to the complaint, following a March 2, 2017 filing of a Form 12b-25 announcing the delay in the filing of its Form 10-K and revealing weaknesses in internal controls, the value of Adeptus shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Adeptus securities purchased on or after April 29, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Google Secures Pentagon AI Deal for Classified Projects
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 



